PATENT CLAIM ANALYSIS

Application Number: 15879999
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-10
Patent Classification: ["514", "210210"]

Abstract:
The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.

Claim (Index 42):
The method of  claim 35 , wherein the myeloproliferative disorder is polycythemia vera, essential thrombocythemia, chronic myelogenous leukemia, myelofibrosis, primary myelofibrosis, post-polycythemia vera/essential thrombocythemia myelofibrosis, post-essential thrombocythemia myelofibrosis or post-polycythemia vera myelofibrosis.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 86.0
- Lexical Diversity: 1.34483
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14465910', '15001826', '14155134', '14798137', '15166380']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8282829570822386
- 35 USC 102 Novelty (BERT): 0.5464074570795697
- Combined Prediction Score: 0.8000954070819718
- Mean Citation Score: 403.687508
- Max Citation Score: 408.53394
- Similarity Product: 315.25720191932555

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test